Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoine Adenis

Showing results (1-10 of 280) with videos related to

Pageof 28
Sort By:
JAMA Oncology|March 30, 2018
Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal CancerAntoine Adenis, Florian Lordick
Bulletin Du Cancer|January 3, 2006
[Targeting the epidermal growth factor receptor in colorectal cancer: clinical results]Antoine Adenis, Mohamed Hebbar
European Journal of Cancer (Oxford, England : 1990)|July 25, 2017
Neoadjuvant chemoradiotherapy for oesophageal cancer: Still looking for a challenger to the CROSS regimenAntoine Adenis, Christophe Mariette
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Fluorouracil should continue to be incorporated in the treatment of localized esophageal cancerAntoine Adenis, Thierry Conroy
The Lancet. Oncology|July 20, 2020
TAS-118 plus oxaliplatin in advanced gastric cancer: is it worth it?Emmanuelle Samalin, Antoine Adenis
Investigational New Drugs|October 22, 2008
Publication biases and phase II trials investigating anticancer targeted therapiesNicolas Penel, Antoine Adenis
Bulletin Du Cancer|February 7, 2004
[Inhibitors of epidermal growth factor receptor and colorectal cancer]Antoine Adenis, Jean-Philippe Peyrat
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 15, 2018
Consolidation chemotherapy after definite concurrent chemoradiation in patients with non-operable esophageal cancer: Is it useful?Antoine Adenis, Florence Castan, Thierry Conroy
The Lancet. Infectious Diseases|January 11, 2024
ChatGPT neglects a neglected diseaseMathieu Nacher, Ugo Françoise, Antoine Adenis
The Lancet. Infectious Diseases|February 15, 2024
ChatGPT does not neglect a neglected disease, if appropriately prompted - Authors' replyMathieu Nacher, Ugo Françoise, Antoine Adenis
Pageof 28

Showing results (1-10 of 280) with videos related to

Sort By:
Pageof 28
JAMA Oncology|March 30, 2018
Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal CancerAntoine Adenis, Florian Lordick
Bulletin Du Cancer|January 3, 2006
[Targeting the epidermal growth factor receptor in colorectal cancer: clinical results]Antoine Adenis, Mohamed Hebbar
European Journal of Cancer (Oxford, England : 1990)|July 25, 2017
Neoadjuvant chemoradiotherapy for oesophageal cancer: Still looking for a challenger to the CROSS regimenAntoine Adenis, Christophe Mariette
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Fluorouracil should continue to be incorporated in the treatment of localized esophageal cancerAntoine Adenis, Thierry Conroy
The Lancet. Oncology|July 20, 2020
TAS-118 plus oxaliplatin in advanced gastric cancer: is it worth it?Emmanuelle Samalin, Antoine Adenis
Investigational New Drugs|October 22, 2008
Publication biases and phase II trials investigating anticancer targeted therapiesNicolas Penel, Antoine Adenis
Bulletin Du Cancer|February 7, 2004
[Inhibitors of epidermal growth factor receptor and colorectal cancer]Antoine Adenis, Jean-Philippe Peyrat
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 15, 2018
Consolidation chemotherapy after definite concurrent chemoradiation in patients with non-operable esophageal cancer: Is it useful?Antoine Adenis, Florence Castan, Thierry Conroy
The Lancet. Infectious Diseases|January 11, 2024
ChatGPT neglects a neglected diseaseMathieu Nacher, Ugo Françoise, Antoine Adenis
The Lancet. Infectious Diseases|February 15, 2024
ChatGPT does not neglect a neglected disease, if appropriately prompted - Authors' replyMathieu Nacher, Ugo Françoise, Antoine Adenis
Pageof 28